The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison (Q44229660)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison |
scientific article |
Statements
1 reference
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison (English)
1 reference
1 reference
A K Burnett
1 reference
A E Hunter
1 reference
D Milligan
1 reference
W J Kell
1 reference
K Wheatley
1 reference
J Yin
1 reference
M F McMullin
1 reference
H Dignum
1 reference
D Bowen
1 reference
N H Russell
1 reference
UK National Cancer Research Institute AML Working Group
1 reference
14 August 2012
1 reference
1 reference
27
1 reference
1
1 reference
75-81
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference